Ditchfield N, Gilchrist FJ, Davies SJ, Carroll W. Strategies to prevent kidney injury from antibiotics in people with cystic fibrosis (Protocol). Cochrane Database of Systematic Reviews 2018, Issue 5. Art. No.: CD013032. DOI: 10.1002/14651858.CD013032.

Randomised controlled trials (RCTs) and quasi- RCTs of both parallel and cross-over design.

Children and adults with a diagnosis of CF confirmed by genetic or sweat testing who are receiving intravenous antibiotics (of any type) for treating an infection

Different types (any class) and dose of intravenous antibiotics. The effect of avoidance of concomitant nephrotoxic drugs (NSAIDs, oral antibiotics and nebulised antibiotics) alongside the intravenous antibiotics will be considered.

Primary outcomes 1. Nephrotoxicty i) serum (blood) creatinine levels ii) creatinine clearance iii) urinary excretion of protein iv) urinary excretion of biomarkers of proximal tubular toxicity Secondary outcomes 1. Eradication of respiratory infection 2. Participant-reported symptom scores 3. Lung function parameters 4. Participant-reported QoL scores 5. Adverse effects of treatment

Antibiotic treatment of early pseudomonas aeruginosa

Antibiotics for pulmonary exacerbations

Inhaled antibiotics in cystic fibrosis

Scheduled antibiotics every 3-4 months / symptom-based treatment